ReviewBiomolecules2026
Research Progress on the Pathogenesis and Diagnostic Biomarkers of Azoospermia.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Azoospermia represents the most severe manifestation of male infertility and is classified into obstructive azoospermia (OA) and non-obstructive azoospermia (NOA). NOA patients experience a lack of sperm due to testicular dysfunction, posing significant challenges in clinical diagnosis and treatment. Recent advancements in molecular biology and high-throughput technologies have led to the discovery and validation of numerous biomarkers, including proteins, non-coding RNAs, genetic polymorphisms, and imaging indicators, which have greatly enhanced the understanding of the pathophysiological mechanisms of azoospermia and facilitated non-invasive diagnostic approaches. This review aims to systematically summarize the pathogenesis of azoospermia and critically evaluate the latest advancements in diagnostic and prognostic biomarkers, including small RNAs, proteomic profiles, genetic markers, and imaging features. The overarching goal is to synthesize this knowledge toward the development of integrated, biomarker-guided strategies for precise diagnosis, prognosis prediction, and improved clinical management of azoospermia, particularly NOA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.